Serum KIM-1 molecular early warning radar: SERS combined with artificial intelligence for accurate early diagnosis of chronic kidney disease
A new biosensor detects early kidney disease markers with high accuracy, offering promise as a point-of-care screening tool.
This study combines SERS immunochromatography to quantify serum kidney injury molecule-1 (KIM-1) with an XGBoost classifier to achieve 98.42% accuracy for early CKD classification. The AI-SERS biosensor approach provides a potentially near-POC tool for CKD screening, though sample size and prospective validation details are absent from the abstract.
What the study was
- Study design
- Diagnostic accuracy study (AI-driven SERS immunochromatography)
- Population
- CKD patients and controls (serum samples)
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Mikrochimica Acta
Why it surfaced
High reported accuracy for CKD using novel SERS+AI biosensor, but sample size undisclosed and prospective validation not described. Promising diagnostic approach.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.